Cirt

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome

Cirt [NCT01594333]

Description: The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).

Drug: Methotrexate; Drug: Placebo

Primary Investigator: Sarembock

Drug/Device Information
Evaluate if low dose Methotrexate will reduce the rates of MI, stroke or cardiovascular deaths in patients with a prior history of CAD, DM or metabolic syndrome
1mg Folic Acid 6 days/wk plus low dose Methotrexate 15-20 mg/wk or placebo
Randomized 1:1
National Heart Lung and Blood Institute